阿莫西林舒巴坦治疗卒中相关性肺炎的临床疗效及安全性

Clinical Efficacy and Safety of Amoxicillin Sulbactam in Treatment of Stroke-associated Pneumonia

目的观察阿莫西林舒巴坦治疗卒中相关性肺炎(SAP)的临床疗效与安全性。方法对2007年12月～2010年12月我院收治的150例卒中相关性肺炎患者纳入本研究。对入选患者给予阿莫西林舒巴坦3.0 g静脉注射,2次/d,疗程7～14 d。观察临床疗效、细菌学疗效及安全性。结果本研究入选病例150例,其中13例由于不良事件致中途停药等原因不能进行临床疗效评价,符合方案的临床疗效可评价病例137例,安全性评价150例。阿莫西林舒巴坦治疗137例卒中相关性肺炎,患者痊愈83例,显效54例,总有效率为89.8%(123/137),细菌总清除率81.1%(43/53)。常见不良反应主要为胃肠道反应(6.0%,9/150)、过敏反应(2.7%,4/150),程度较轻,停药后消失。结论阿莫西林舒巴坦3.0 g静脉注射,每日2次,可有效治疗卒中相关性肺炎,且不良反应少。

Objective To observe the clinical efficacy and safety of amoxicillin sulbactam in the treatment of patients with stroke-associated pneumonia （SAP）. Methods We studied 150 patients with SPA hospitalized from Dec. 2007 to Dec. 2010,Amoxicillin sulbactam intravenous injection was administered 3.0 g twice daily. The duration of treatment was 7 - 14 days. Clinical Jficacy and safety were recorded. Results 150 patients with SAP were enrolled at the beginning,and only 137 were evaluable at the endpoint. The total effective rate of amoxicillin sulbactam was 81.19% （123/137）. The total bacterial eradication rate was 81.1% （43/53）. The most common adverse drug reactions were gastrointestinal disorders （6.0% , 9/ 150） and hypersensitive reaction （2. 7% 4/150）, which were mild and disappeared after stopping administration. Conclusion Intravenous amoxicillin sulbactam with a dose of 3.0g twice daily is effective and safe in treating SAP with low adverse reactions.